Creative Commons source reading · Epilepsy and seizure classification
Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Drug-Resistant Epilepsy in the MORE Multicenter Patient Registry.
Jukka Peltola; Albert J Colon; José Pimentel; Volker A Coenen; Antonio Gil-Nagel; Antonio Gonçalves Ferreira; Kai Lehtimäki; Philippe Ryvlin; Rod S Taylor; Linda Ackermans; Jacqueline Ardesch; Carla Bentes; Magdalena Bosak; Jorge G Burneo; Clara Chamadoira; Christian E Elger; Loránd Erőss; Dániel Fabo; Howard Faulkner; Jacek Gawlowicz; Alireza Gharabaghi; Maurizio Iacoangeli; Jozsef Janszky; Soila Järvenpää; Elisabeth Kaufmann; Kuan H Kho; Eva Kumlien; Helmut Laufs; Christian Lettieri; Paulo Linhares; Soheyl Noachtar; Andrew Parrent; Ekaterina Pataraia; Nikunj K Patel; Ana Rita Peralta; Attila Rácz; Alexandre Rainha Campos; Ricardo Rego; Riccardo A Ricciuti; Sabine Rona; Rob P W Rouhl; Andreas Schulze-Bonhage; Rick Schuurman; Mathieu Sprengers; Albert Sufianov; Yasin Temel; Tom Theys; Wim Van Paesschen; Dirk Van Roost; Rui Vaz; Kristl Vonck; Louis Wagner; Jack Zwemmer; Abdallah Abouihia; Thomas C Brionne; Frans Gielen; Paul A J M Boon; MORE Study Group
Originally published in Neurology · 2023-03-16
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Background and objectives The efficacy of deep brain stimulation of the anterior nucleus of the thalamus (ANT DBS) in patients with drug-resistant epilepsy (DRE) was demonstrated in the double-blind Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy randomized controlled trial. The Medtronic Registry for Epilepsy (MORE) aims to understand the safety and longer-term effectiveness of ANT DBS therapy in routine clinical practice. Methods MORE is an observational registry collecting prospective and retrospective clinical data. Participants were at least 18 years old, with focal DRE recruited across 25 centers from 13 countries. They were followed for at least 2 years in terms of seizure frequency (SF), responder rate (RR), health-related quality of life (Quality of Life in Epilepsy Inventory 31), depression, and safety outcomes. Results Of the 191 patients recruited, 170 (mean [SD] age of 35.6 [10.7] years, 43% female) were implanted with DBS therapy and met all eligibility criteria. At baseline, 38% of patients reported cognitive impairment.
Results
Patient enrollment was from February 21, 2012, until April 30, 2017. The last data were collected on June 19, 2019. A total of 191 (APS) patients were recruited by 25 centers in 13 countries, with recruitment varying from 1 to 28 patients per site. Most of the 170 FAS subjects (157, 92.4%) completed follow-up visit 5 (scheduled around 2 years after implantation) for a median of 2 years of follow-up. Reasons for 13 patients withdrawn before follow-up visit 5 are given in Figure 1.
Discussion
The MORE multinational registry provides systematically collected real-world data about the safety and effectiveness of ANT DBS therapy in patients with DRE. Our results support the clinical efficacy and safety of ANT DBS therapy previously reported in the SANTE randomized controlled trial and single-center experiences. Key findings include a 33.1% median monthly SF reduction after 2 years of treatment; however, it was observed that seizure outcomes of the patients were affected by the treatment center experience.
Editorial reading guide
- Which patient population and reference standard did the authors use?
- Was the finding validated in a separate cohort, and how might patient selection affect it?
